News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rainbow BioSciences, LLC Target Amarantus BioSciences, Inc. Reports Positive Pre-Clinical Results of Parkinson's Treatment


5/2/2012 10:15:58 AM

NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), announced today that its current joint venture target, Amarantus BioSciences, Inc., has achieved positive results in a pre-clinical experiment demonstrating the potential of its new Parkinson’s disease therapy currently in development.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES